Barrier Therapeutics, Inc. (BTRX) Introduces Dual-Component Xolegel CorePak(TM) for Seborrheic Dermatitis
7/28/2008 9:33:11 AM
PRINCETON, NJ--(Marketwire - July 28, 2008) - Barrier Therapeutics, Inc. (NASDAQ: BTRX) announced today the introduction of Xolegel CorePak™ for the treatment of seborrheic dermatitis. Now, patients with this chronic skin condition need only one prescription to get quick itch relief and to safely manage the overall condition long term.
comments powered by